Apogee Therapeutics reported second quarter 2026 financial results and announced that AbbVie will acquire the company for $135.11 per share in cash, representing a total equity value of approximately $10.9 billion. The transaction is expected to close in the third quarter of 2026, subject to shareholder approval and regulatory clearance. Financially, the company reported a net loss of $85.9 million for the quarter ended June 30, 2026, compared to a net loss of $66.1 million in the prior year period. Research and development expenses increased to $67.3 million from $55.7 million, while general and administrative expenses rose to $24.3 million from $17.5 million. Cash and equivalents stood at $1.3 billion as of June 30, 2026. Additionally, the company highlighted positive Phase 2 results for its lead asset zumilokibart in atopic dermatitis and announced plans to initiate Phase 3 trials this year.
